Gilead Sciences (NQ:GILD)

XLV offers exposure to the broader healthcare sector, while IBB targets biotech innovators. Here's how the two stack up on risk, returns, and diversification.

Topics ETFs

XLV vs IBB: How Healthcare Diversification Compares to Biotech Concentration ↗

September 24, 2026

Fidelity Healthcare ETF (FHLC) vs. VanEck Biotech ETF (BBH): Which Fund Is the Better Buy? ↗

Topics ETFs

September 24, 2026

VanEck's concentrated 25-stock biotech portfolio surged 40.5% in one year, but Fidelity's diversified 365-holding fund delivered superior risk-adjusted returns with half the volatility.

IBBQ offers concentrated biotech exposure with lower costs and stronger recent returns, while IYH provides broader sector diversification and higher dividend income.

Topics ETFs

Gilead Sciences (NASDAQ:GILD): A Quality Dividend Stock for Income Investors ↗

September 04, 2026

Via Chartmill

What's going on in today's after hours session: S&P500 movers ↗

August 27, 2026

Via Chartmill

Better Healthcare ETF: Invesco's Biotech-Focused IBBQ vs. iShares' Broad IYH ↗

September 22, 2026

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff...

Topics ETFs

1 Cash-Producing Stock on Our Buy List and 2 We Find Risky

September 22, 2026

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) said it plans to begin registrational studies next year for its lead T-cell engager, gamgertamig, following a broad restructuring of...

Lakefront Biotherapeutics Targets 2027 Registrational Trials for Gamgertamig ↗

September 21, 2026

Gilead Sciences (NASDAQ:GILD) executives outlined plans to expand the company’s HIV prevention and treatment franchises while advancing oncology and inflammation programs, with Chairman and Chief...

Gilead Sciences Sees Yeztugo Powering HIV Growth as Oncology Pipeline Advances ↗

September 15, 2026

PBE vs. RSPH: Is a Biotech ETF or Equal-Weight Healthcare ETF the Better Choice for Investors? ↗

Topics Intellectual Property

September 15, 2026

PBE offers higher income and stronger returns, while RSPH provides broader diversification with lower costs and drawdown risk.

If You Invested $100 In Gilead Sciences Stock 20 Years Ago, You Would Have This Much Today ↗

Topics ETFs

September 10, 2026

Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 2.42% on an annualized basis producing an average annual return of 11.56%. Currently, Gilead Sciences has a market...

Via Benzinga

Gilead Sciences Sees Sunlenca Launch Fueling Long-Term HIV Growth ↗

September 10, 2026

Gilead Sciences (NASDAQ:GILD) CFO Andy Dickinson told attendees at the Cantor Global Healthcare Conference that the company sees continued growth opportunities across its HIV prevention and treatment...

Gilead Sciences (NASDAQ:GILD) Chief Medical Officer Dietmar Berger outlined the company’s priorities across HIV, oncology and inflammation at the Wells Fargo conference, describing a portfolio that has...

Gilead Sciences Eyes HIV, Oncology Catalysts as Pipeline Enters Execution Mode ↗

September 10, 2026

While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor exec...

1 S&P 500 Stock on Our Buy List and 2 Facing Challenges

September 09, 2026

Gilead Sciences Just Won Its Third FDA Approval in Less Than 4 Months. Is the Stock Still Underrating This Turnaround Play? ↗

Topics Stocks

September 05, 2026

Gilead Sciences is branching out beyond its HIV franchise into oncology and immunology therapies.

Invesco's biotech fund surged 56.4% in one year, while Fidelity's broader healthcare portfolio offers lower costs and steadier returns.

Healthcare ETF Comparison: Fidelity's FHLC vs. Invesco's Biotech-Focused IBBQ ↗

September 02, 2026

The FDA approved Gilead Sciences' Bixlenvo, a new once-daily single tablet regimen for virologically suppressed adults treating HIV.

Topics ETFs

FDA Approves Gilead's New Single Tablet HIV Regimen ↗

August 31, 2026

Via Benzinga

3 Unpopular Stocks with Open Questions

August 31, 2026

Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cord...

Which Healthcare ETF Offers the Better Growth Outlook: VanEck Biotech or Invesco Pharmaceuticals? ↗

August 28, 2026

VanEck focuses on a clutch of biotech leaders with lower fees; Invesco tracks a select group of pharma companies with higher dividend yield and stronger five-year returns.

Gilead Sciences Has Snapped Out of Its Slump -- and 1 Catalyst Is Doing Most of the Heavy Lifting ↗

Topics ETFs

August 26, 2026

Since earnings, investors have focused mainly on the biotech company's growth potential with its HIV PrEP medicines.

These healthcare leaders are unlikely to suspend their dividend programs.

3 Dividend Stocks to Hold for the Next 10 Years ↗

August 25, 2026

Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to conv...

Topics Artificial Intelligence Intellectual Property

3 Unprofitable Stocks with Questionable Fundamentals

August 25, 2026

Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 5 years by 4.4% on an annualized basis producing an average annual return of 15.54%. Currently, Gilead Sciences has a market...

$1000 Invested In Gilead Sciences 5 Years Ago Would Be Worth This Much Today ↗

August 24, 2026

Via Benzinga

Which Biotech ETF Is a Better Buy: Concentrated Bet or Broad Basket? ↗

August 22, 2026

VanEck's concentrated 25-stock approach offers higher individual company exposure, while Invesco's broader 251-position portfolio delivered 47.4% returns over the past year.

PBE concentrates on 31 companies and offers a higher dividend yield, while IBBQ spreads risk across 251 holdings at a fraction of the cost.

Topics ETFs

IBBQ vs. PBE: Which Biotech ETF Is the Better Buy? ↗

August 21, 2026

These stocks can be safe-haven investments to hide out in amid market turmoil.

Topics ETFs

Worried About a Market Crash? These 3 Stocks Beat the S&P 500 in 2008 and 2022 ↗

August 19, 2026

One offers concentrated exposure to 29 pharma giants with lower volatility, while the other provides broader diversification across 251 biotech companies at a cheaper cost.

Topics Economy Stocks

Invesco Nasdaq Biotech vs. Invesco Pharma: How Do These ETFs Stack Up? ↗

August 19, 2026

Gilead Sciences Has Quietly Become One of the Most Underrated Turnaround Stories in Healthcare. Here's Why Wall Street Is Excited. ↗

Topics ETFs

August 18, 2026

The company's HIV franchise is stronger than ever, and it's adding a stable of oncology drugs.

Over the last six months, Gilead Sciences’s shares have sunk to $137.77, producing a disappointing 11.3% loss - a stark contrast to the S&P 500’s 13.1% gain....

Gilead Sciences (GILD): Buy, Sell, or Hold Post Q2 Earnings?

August 14, 2026

Enrollment completed six months early; $1.5B cash runway into 2029.

Topics Stocks

Kymera Therapeutics (KYMR) Q2 2026 Earnings Call Transcript ↗

August 12, 2026